Pulmatrix, Inc. (NASDAQ:PULM – Get Free Report) was the target of a large increase in short interest in the month of November. As of November 15th, there was short interest totalling 411,600 shares, an increase of 5,697.2% from the October 31st total of 7,100 shares. Based on an average daily volume of 420,600 shares, the short-interest ratio is currently 1.0 days. Currently, 11.3% of the shares of the company are short sold.
Pulmatrix Stock Performance
PULM stock opened at $7.34 on Thursday. The company has a market cap of $26.79 million, a price-to-earnings ratio of -2.81 and a beta of 0.99. The business’s 50-day moving average is $2.82 and its two-hundred day moving average is $2.30. Pulmatrix has a fifty-two week low of $1.55 and a fifty-two week high of $8.44.
Wall Street Analyst Weigh In
Separately, StockNews.com initiated coverage on Pulmatrix in a report on Tuesday. They set a “hold” rating on the stock.
About Pulmatrix
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Read More
- Five stocks we like better than Pulmatrix
- What is a buyback in stocks? A comprehensive guide for investors
- DICK’S Sporting Goods: The Under-the-Radar Buy-and-Hold Winner
- What is the Australian Securities Exchange (ASX)
- 2 Cheap Quantum Computing Stocks to Buy Instead of Chasing IonQ
- Best Stocks Under $10.00
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
